0001209191-23-026069.txt : 20230428 0001209191-23-026069.hdr.sgml : 20230428 20230428165451 ACCESSION NUMBER: 0001209191-23-026069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230426 FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CLARKE JOHN K CENTRAL INDEX KEY: 0001219015 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 23867734 MAIL ADDRESS: STREET 1: C/O CARDINAL HEALTH PARTNERS STREET 2: 221 NASSAU STREET CITY: PRINCETON STATE: NJ ZIP: 08542 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10240 SORRENTO VALLEY ROAD STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8587318389 MAIL ADDRESS: STREET 1: 10240 SORRENTO VALLEY ROAD STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-26 0 0001339970 aTYR PHARMA INC LIFE 0001219015 CLARKE JOHN K C/O ATYR PHARMA, INC. 10240 SORRENTO VALLEY ROAD, SUITE 300 SAN DIEGO CA 92121 1 0 0 0 0 Common Stock 2023-04-26 4 M 0 6000 A 19797 D Restricted Stock Unit 2023-04-26 4 M 0 6000 0.00 D Common Stock 0 0 D Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. RSUs convert into common stock on a one-for-one basis. Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution. The RSUs fully vested one year from the grant date which was April 26, 2022. Nancy E. Denyes, Attorney-In-Fact 2023-04-28